Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas

NCT04921904 is registered in ClinicalTrials.gov with Baylor Research Institute as lead sponsor.

NCT NCT04921904
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04921904 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas
Lead sponsor
Baylor Research Institute
Phase
Phase 1/2
Overall status
Completed
Start date
June 11, 2021
Completion date
August 14, 2025
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic esophageal adenocarcinoma, metastatic gastroesophageal junction adenocarcinoma